Keywords: Janssen, Pharmacyclics, Johnson & Johnson, Ibrutinib, USA, FDA, Breakthrough status, B-cell malignancies
US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib
Article | 14 February 2013
US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that the US Food and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
